Amedica Corporation announced several new additions to its executive management team to help guide the company's efforts as Amedica shifts the standard of care for interbody fusion devices toward proprietary Silicon Nitride (Si(3) N(4)) ceramic. Four strategic appointments, including a Senior Vice President of Market Development, Vice President of Marketing, a Senior Vice President of Sales, and a Chief Legal and Compliance Officer, have been added to the executive team to help execute on the company's business objectives. As Amedica works to expand the utilization of Silicon Nitride in other orthopaedic applications, the hiring of experienced executives will be a key to success.

Vytas Rupinskas joins Amedica as Vice President of Marketing. Mr. Rupinskas brings more than twenty five years of marketing experience in the orthopedic, spinal and neuromodulation medical device markets previously holding senior positions at St Jude Medical, DePuy Orthopedics, DePuy International and DePuy Spine. Paul Sendro, formerly Senior Vice President of Sales for Amedica, will now be the company's strategic market development initiatives.

Paul has over 20 years of experience in the orthopaedic, trauma and spine medical device industries. He has held leadership positions at numerous well established companies such as US Spine, Vertebron, Blackstone Medical, Stryker Inc. and Synthes USA. Jim Abraham joins Amedica as Senior Vice President of Sales bringing with him over 25 years of experience in the orthopedic, trauma, spine, biologics and dental markets.

He comes to Amedica from Stryker Orthopedics and has previously held a number of executive positions at companies such as IsoTis Orthobiologics, Regeneration Technologies, Encore Orthopedics and Sulzermedica. Kevin Ontiveros joins Amedica as Chief Legal and Compliance Officer. Kevin has over 20 years of experience serving as in-house and outside corporate counsel for publicly traded and privately held medical device and biotechnology/pharmaceutical companies such as ImaRx Therapeutics Inc. (IMRX) and NPS Pharmaceuticals Inc. (NPSP).